PRESS RELEASE

Munich, 4 July 2023

A team of honert provided comprehensive legal advice to smartbax GmbH as part of a seven-figures seed financing round. Within this seed financing round Boehringer Ingelheim Venture Fund (BIVF) and High-Tech Gründerfonds (HTGF) invested in smartbax GmbH.

The biotech company smartbax was founded in 2021 by Dr. Robert Macsics, Marco Janezic and Prof. Dr. Stephan Sieber and develops next generation antibiotics. It uses a unique, dual-targeted approach that both inhibits essential processes in the bacterial energy metabolism and creates a stimulation of the bacteria’s protein secretion that leads to the cells’ self-digestion. The goal of smartbax is to promote and develop innovative antibiotics against multi-drug resistant bacteria. The provided funds will be used to finance preclinical studies on their small-molecule antibiotics and to expand the scientific team.

ADVISORS:

honert (Munich): Dr. Kai-Klemens Wehlage (lead) and Peter Kipp (both venture capital/corporate law)

FOR FURTHER INFORMATION PLEASE CONTACT:

Dr. Kai-Klemens Wehlage
honert münchen PartG mbB
rechtsanwälte wirtschaftsprüfer steuerberater Theatinerstrasse 14
80333 Munich
Tel. +49 (89) 388 381 0
[email protected]